The latest price target for Harmony Biosciences Hldgs (NASDAQ:HRMY) was reported by Mizuho on December 1, 2025. The analyst firm set a price target for $46.00 expecting HRMY to rise to within 12 months (a possible 18.47% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Harmony Biosciences Hldgs (NASDAQ:HRMY) was provided by Mizuho, and Harmony Biosciences Hldgs maintained their outperform rating.

There is no last upgrade for Harmony Biosciences Hldgs

The last downgrade for Harmony Biosciences Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from N/A to $30 for Harmony Biosciences Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harmony Biosciences Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harmony Biosciences Hldgs was filed on December 1, 2025 so you should expect the next rating to be made available sometime around December 1, 2026.

While ratings are subjective and will change, the latest Harmony Biosciences Hldgs (HRMY) rating was a maintained with a price target of $39.00 to $46.00. The current price Harmony Biosciences Hldgs (HRMY) is trading at is $38.83, which is out of the analyst’s predicted range.